EP4188959A4 - ANTIVARIABLE MUC1* ANTIBODIES AND USES THEREOF - Google Patents

ANTIVARIABLE MUC1* ANTIBODIES AND USES THEREOF Download PDF

Info

Publication number: EP4188959A4
Authority: EP; European Patent Office
Prior art keywords: antivariable; muc1; antibodies; antivariable muc1
Prior art date: 2020-07-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP21850106.2A

Other languages

German (de)

French (fr)

Other versions

EP4188959A1 (en

Inventor

Cynthia Bamdad

Benoit Smagghe

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Minerva Biotechnologies Corp

Original Assignee

Minerva Biotechnologies Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2020-07-29

Filing date

2021-07-27

Publication date

2024-08-14

2021-07-27 Application filed by Minerva Biotechnologies Corp filed Critical Minerva Biotechnologies Corp

2023-06-07 Publication of EP4188959A1 publication Critical patent/EP4188959A1/en

2024-08-14 Publication of EP4188959A4 publication Critical patent/EP4188959A4/en

Status Pending legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4256—Tumor associated carbohydrates
- A61K40/4257—Mucins, e.g. MUC-1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/11—Antigen recognition domain
- A61K2239/13—Antibody-based
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/22—Intracellular domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
General Engineering & Computer Science (AREA)
Hematology (AREA)
Microbiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicinal Preparation (AREA)

EP21850106.2A 2020-07-29 2021-07-27 ANTIVARIABLE MUC1* ANTIBODIES AND USES THEREOF Pending EP4188959A4 (en)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US202063058044P	2020-07-29	2020-07-29
US202063122234P	2020-12-07	2020-12-07
US202163151380P	2021-02-19	2021-02-19
US202163173083P	2021-04-09	2021-04-09
US202163184724P	2021-05-05	2021-05-05
PCT/US2021/071017 WO2022027039A1 (en)	2020-07-29	2021-07-27	Anti-variable muc1* antibodies and uses thereof

Publications (2)

Publication Number	Publication Date
EP4188959A1 EP4188959A1 (en)	2023-06-07
EP4188959A4 true EP4188959A4 (en)	2024-08-14

Family

ID=80036184

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP21850106.2A Pending EP4188959A4 (en)	2020-07-29	2021-07-27	ANTIVARIABLE MUC1* ANTIBODIES AND USES THEREOF

Country Status (8)

Country	Link
EP (1)	EP4188959A4 (en)
JP (2)	JP7719855B2 (en)
KR (1)	KR20230059789A (en)
CN (1)	CN116234828A (en)
AU (1)	AU2021316042A1 (en)
CA (1)	CA3187555A1 (en)
IL (1)	IL300252A (en)
WO (1)	WO2022027039A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20230031981A (en)	2019-05-14	2023-03-07	프로벤션 바이오, 인코포레이티드	Methods and compositions for preventing type 1 diabetes
IL298999A (en)	2020-06-11	2023-02-01	Provention Bio Inc	Methods and compositions for preventing type 1 diabetes
US20230242678A1 (en)	2020-06-26	2023-08-03	Minerva Biotechnologies Corporation	Anti-nme antibody and method of treating cancer or cancer metastasis
IL316221A (en)	2022-04-12	2024-12-01	Minerva Biotechnologies Corp	Anti-variable muc1* antibodies and uses thereof
US20240261406A1 (en)	2023-02-02	2024-08-08	Minerva Biotechnologies Corporation	Chimeric antigen receptor compositions and methods for treating muc1* diseases
WO2025049494A1 (en)	2023-08-29	2025-03-06	Minerva Biotechnologies Corporation	Bacterial nme7 orthologs and uses thereof
WO2025080693A1 (en) *	2023-10-11	2025-04-17	Minerva Biotechnologies Corporation	Anti-muc1* antibody drug complexes and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20180112007A1 (en) *	2015-02-10	2018-04-26	Minerva Biotechnologies Corporation	Humanized anti-muc1* antibodies
WO2019104306A1 (en) *	2017-11-27	2019-05-31	Minerva Biotechnologies Corporation	Humanized anti-muc1* antibodies and direct use of cleavage enzyme
WO2019133969A2 (en) *	2017-12-29	2019-07-04	Memorial Sloan-Kettering Cancer Center	Enhanced chimeric antigen receptors and uses thereof
WO2020146902A2 (en) *	2019-01-11	2020-07-16	Minerva Biotechnologies Corporation	Anti-variable muc1* antibodies and uses thereof

2021
- 2021-07-27 WO PCT/US2021/071017 patent/WO2022027039A1/en not_active Ceased
- 2021-07-27 IL IL300252A patent/IL300252A/en unknown
- 2021-07-27 EP EP21850106.2A patent/EP4188959A4/en active Pending
- 2021-07-27 AU AU2021316042A patent/AU2021316042A1/en active Pending
- 2021-07-27 KR KR1020237006591A patent/KR20230059789A/en active Pending
- 2021-07-27 CA CA3187555A patent/CA3187555A1/en active Pending
- 2021-07-27 CN CN202180067049.7A patent/CN116234828A/en active Pending
- 2021-07-27 JP JP2023506494A patent/JP7719855B2/en active Active
2024
- 2024-06-28 JP JP2024105523A patent/JP2024156662A/en active Pending

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20180112007A1 (en) *	2015-02-10	2018-04-26	Minerva Biotechnologies Corporation	Humanized anti-muc1* antibodies
WO2019104306A1 (en) *	2017-11-27	2019-05-31	Minerva Biotechnologies Corporation	Humanized anti-muc1* antibodies and direct use of cleavage enzyme
WO2019133969A2 (en) *	2017-12-29	2019-07-04	Memorial Sloan-Kettering Cancer Center	Enhanced chimeric antigen receptors and uses thereof
WO2020146902A2 (en) *	2019-01-11	2020-07-16	Minerva Biotechnologies Corporation	Anti-variable muc1* antibodies and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HUGHES-PARRY HANNAH E. ET AL: "The Evolving Protein Engineering in the Design of Chimeric Antigen Receptor T Cells", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 21, no. 1, 27 December 2019 (2019-12-27), Basel, CH, pages 204, XP055977541, ISSN: 1661-6596, DOI: 10.3390/ijms21010204 *
MAJZNER ROBBIE G. ET AL: "Tuning the Antigen Density Requirement for CAR T-cell Activity", CANCER DISCOVERY, vol. 10, no. 5, 19 March 2020 (2020-03-19), US, pages 702 - 723, XP055883616, ISSN: 2159-8274, DOI: 10.1158/2159-8290.CD-19-0945 *
See also references of WO2022027039A1 *
Y. ZHAO ET AL: "A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity", THE JOURNAL OF IMMUNOLOGY, vol. 183, no. 9, 1 November 2009 (2009-11-01), pages 5563 - 5574, XP055081967, ISSN: 0022-1767, DOI: 10.4049/jimmunol.0900447 *
ZHENG WENTING ET AL: "PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells", BLOOD CANCER JOURNAL, NATURE PUBLISHING GROUP UK, LONDON, vol. 32, no. 5, 2 February 2018 (2018-02-02), pages 1157 - 1167, XP036497308, ISSN: 0887-6924, [retrieved on 20180202], DOI: 10.1038/S41375-017-0008-6 *

Also Published As

Publication number	Publication date
CN116234828A (en)	2023-06-06
JP2024156662A (en)	2024-11-06
CA3187555A1 (en)	2022-02-03
JP2023537326A (en)	2023-08-31
KR20230059789A (en)	2023-05-03
WO2022027039A1 (en)	2022-02-03
IL300252A (en)	2023-03-01
JP7719855B2 (en)	2025-08-06
AU2021316042A1 (en)	2023-03-30
EP4188959A1 (en)	2023-06-07

Publication	Publication Date	Title
EP4188959A4 (en)	2024-08-14	ANTIVARIABLE MUC1* ANTIBODIES AND USES THEREOF
EP3759143A4 (en)	2022-03-02	ANTI-TIGIT ANTIBODIES AND USES THEREOF
EP3740224A4 (en)	2022-05-04	ANTI-LILRB ANTIBODIES AND USES THEREOF
EP4141030A4 (en)	2024-09-04	ANTI-CD73 ANTIBODIES AND USE THEREOF
IL284772A (en)	2021-08-31	Antibodies against variable *muc1 and uses thereof
EP4359442A4 (en)	2025-10-15	ANTI-CCR8 ANTIBODIES AND USES THEREOF
EP4071172A4 (en)	2023-10-18	ANTI-LILRB1 ANTIBODIES AND USES THEREOF
EP3735427A4 (en)	2021-09-15	ANTI-MCT1 ANTIBODIES AND USES THEREOF
EP4039708A4 (en)	2023-11-08	ANTI-CLL-1 ANTIBODIES AND USE THEREOF
EP3904382A4 (en)	2022-07-13	ANTI-IL-23P19 ANTIBODIES AND USES THEREOF
EP4025609A4 (en)	2023-10-04	ANTI-STEAP1 ANTIBODIES AND USES THEREOF
EP4302777A4 (en)	2025-07-02	ANTI-CLDN6 ANTIBODIES AND USE THEREOF
EP4142793A4 (en)	2024-08-28	ABCB5-SPECIFIC ANTIBODIES AND USES THEREOF
EP4132569A4 (en)	2024-07-31	ANTI-PHF-TAU ANTIBODIES AND USES THEREOF
EP4126938A4 (en)	2024-04-10	SIGLEC15-BINDING ANTIBODIES AND USES THEREOF
EP4319822A4 (en)	2024-10-16	ANTIVARIABLE MUC1* ANTIBODIES AND USES THEREOF
EP3790586A4 (en)	2022-01-19	ANTI-DLL3 ANTIBODIES AND USES THEREOF
EP3962954A4 (en)	2023-01-18	ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF
EP4247419A4 (en)	2024-11-06	ANTI-MARCO ANTIBODIES AND USES THEREOF
EP4244255A4 (en)	2024-12-25	ANTI-TIGIT ANTIBODIES AND USES THEREOF
EP4001308A4 (en)	2023-08-23	ANTI-TIGIT ANTIBODIES AND USES THEREOF
EP4396224A4 (en)	2025-11-12	ANTI-DLL3 ANTIBODIES AND USES THEREOF
EP4146272A4 (en)	2024-10-23	COVID-19 ANTIBODIES AND USES THEREOF
EP4340879A4 (en)	2025-03-26	C1S-BINDING ANTIBODIES AND USES THEREOF
EP4321535A4 (en)	2025-04-23	ANTI-CNTN4 ANTIBODIES AND USE THEREOF

Legal Events

Date	Code	Title	Description
2022-02-04	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2023-05-05	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2023-05-05	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2023-06-07	17P	Request for examination filed	Effective date: 20230227
2023-06-07	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2023-08-23	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230719
2023-11-08	DAV	Request for validation of the european patent (deleted)
2023-11-08	DAX	Request for extension of the european patent (deleted)
2024-08-14	A4	Supplementary search report drawn up and despatched	Effective date: 20240715
2024-08-14	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 39/00 20060101ALI20240709BHEP Ipc: A61P 35/00 20060101ALI20240709BHEP Ipc: C07K 14/71 20060101ALI20240709BHEP Ipc: C07K 16/30 20060101ALI20240709BHEP Ipc: C07K 16/28 20060101AFI20240709BHEP
2025-04-18	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2025-05-21	17Q	First examination report despatched	Effective date: 20250417